This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Ranked Momentum Stocks to Buy for May 18th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, May 18th
Healthcare Tech & Robotics ETFs in Focus amid COVID-19 Crisis
by Neena Mishra
The pandemic will forever transform our lives; here are some areas that may benefit.
Looking for a Growth Stock? 3 Reasons Why Quidel (QDEL) is a Solid Choice
by Zacks Equity Research
Quidel (QDEL) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Is Quidel (QDEL) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (QDEL) Outperforming Other Medical Stocks This Year?
The Zacks Analyst Blog Highlights: Pluralsight, Quidel, Vista Outdoor, SunOpta and Nautilus
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pluralsight, Quidel, Vista Outdoor, SunOpta and Nautilus
The Zacks Analyst Blog Highlights: Wayfair, Chegg, Moderna, Quidel and Clorox
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Wayfair, Chegg, Moderna, Quidel and Clorox
5 Stocks to Buy as America Prepares to Reopen Economy
by Zacks Equity Research
As the U.S. economy prepares to reopen, here are five growth stocks to invest in to earn significantly higher returns.
An Outstanding Week for Market Amid Record Job Losses: 5 Picks
by Nalak Das
Market's worst is behind us as negative estimates are already factored in valuations.
Quidel (QDEL) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Quidel (QDEL) delivered earnings and revenue surprises of 22.00% and 11.16%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Quidel (QDEL) This Earnings Season?
by Zacks Equity Research
Quidel (QDEL) is expected to have gained from its Molecular Diagnostic Solutions business in Q1.
Trump Pushes for US-Made Medical Products: 4 Winners
by Ritujay Ghosh
An executive order to address the lack of medical product manufacturing in the United States could in a way boost manufacturing and sales of home-grown goods.
Quidel (QDEL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Quidel (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quidel (QDEL) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Quidel (QDEL) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
The Zacks Analyst Blog Highlights: Danaher, Quidel, Aytu BioScience, QIAGEN and Co-Diagnostics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Danaher, Quidel, Aytu BioScience, QIAGEN and Co-Diagnostics
Coronavirus Test Kit Demand to Drive These 3 Stocks
by Zacks Equity Research
Point-of-care testing enables better patient triage, bed management, and patient care decisions. Here are three stocks to benefit as demand rises.
Quidel (QDEL) Looks Good: Stock Adds 10.8% in Session
by Zacks Equity Research
Quidel (QDEL) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.
Earnings Preview: Quidel (QDEL) Q4 Earnings Expected to Decline
by Zacks Equity Research
Quidel (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quidel (QDEL) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Quidel (QDEL) delivered earnings and revenue surprises of 7.69% and 0.69%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Quidel (QDEL) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Quidel (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quidel (QDEL) Q2 Earnings Meet Estimates
by Zacks Equity Research
Quidel (QDEL) delivered earnings and revenue surprises of 0.00% and 0.26%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Quidel (QDEL) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Quidel (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medical Products Industry Outlook: Growth Prospects Radiant
by Trina Mukherjee
Growth prospects look bright for the Zacks Medical Products industry, thanks to AI, Medical Mechatronics and Robotics and rampant M&As.
QDEL vs. BAX: Which Stock Is the Better Value Option?
by Zacks Equity Research
QDEL vs. BAX: Which Stock Is the Better Value Option?
Masimo's O3 Oximetry Gets FDA Nod, Boosts Patient Monitoring
by Zacks Equity Research
Masimo (MASI) gets FDA nod for its O3 Regional Oximetry that will help in delivering accurate measurement with respect to neonatal patients.